Erschienen in:
01.02.2011 | Letter to the Editor
A case of metastatic breast cancer successfully treated with lapatinib plus capecitabine therapy
verfasst von:
Umut Kefeli, Ahmet Bilici, Bala Basak Oven Ustaalioglu, Aysegul Ucuncu Kefeli, Mahmut Emre Yildirim, Mesut Seker, Mahmut Gumus
Erschienen in:
Archives of Gynecology and Obstetrics
|
Ausgabe 2/2011
Einloggen, um Zugang zu erhalten
Excerpt
Lapatinib is a dual tyrosine-kinase inhibitor which targets both human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR) tyrosine kinases [
1]. It has the advantage of being administered orally. Lapatinib showed promising results both in trastuzumab-naive and in pretreated HER2-positive advanced breast cancer [
2‐
5]. It has been shown that lapatinib plus capecitabine is superior to capecitabine alone in HER2-positive advanced breast cancer patients previously treated with anthracycline, taxane and trastuzumab [
6]. Herein, we describe a case of metastatic breast cancer patient who had resistance to trastuzumab and showed a clinically complete response to lapatinib with capecitabine therapy. …